The mechanism of the anticancer function of M1 macrophages and their use in the clinic

Chinese Journal of Cancer

Volumn 31, Issue 12, 2012, Pages 557-563

  Pan, Xing Qing ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anticancer; Chitotriosidase; Macrophages; Protease

Indexed keywords

BILE EXTRACT; CHITOTRIOSIDASE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 4; LENTINAN; UNCLASSIFIED DRUG; VIRULIZIN;

ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CARCINOGENESIS; CELL INFILTRATION; CELL STIMULATION; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG MECHANISM; ENZYME SYNTHESIS; EXPERIMENTAL ANIMAL; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; LACTIC ACID BACTERIUM; LOW DRUG DOSE; M1 MACROPHAGE; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION INHIBITION; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SARCOMA; TUMOR CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHITINASE; CYCLOPHOSPHAMIDE; HEXOSAMINIDASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGE ACTIVATION; MACROPHAGES; NEOPLASMS; PEPTIDE HYDROLASES; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 84871144194     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10046     Document Type: Review

References (91)

1. Luo Y, Kmudson MJ. Mycobacterium bovis Bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol, 2010,2010:357591.
2. Bonnotte B, Larmonier N, Favre N, et al. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol, 2001,167: 5077-5083.
3. Bhaumik S, Mitra R, Varalakshmi C, et al. Activated macrophages migrate to subcutaneous tumor site via the peritoneurm: a novel route of cell trafficking. Exp Cell Res, 2001,266:44-52.
4. Cheenpracha S, Park EJ, Rostama B, et al. Inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-activated murine macrophage RAW 264.7 cells by the norsesterterpene peroxide, epimuqubilin A. Mar Drugs, 2010,8:429-437.
5. Harwix S, Andreesen R, Ferber E, et al. Human macrophages secrete a tumoricidal activity distinct from tumor necrosis necrosis factor-α and reactive nitrogen intermediates. Res Immunol, 1992,143:89-94.
6. Adams DO, Kao KJ, Farb R, et al. Effector mechanism of cytolytically activated macrophages II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J Immunol, 1980,124:293-300.
7. Pan XQ, Hardy J, Lee R, et al. Chitinase selectively attacks tumor cells and cures cancer transplanted models mice. Minerva Medica, 2001,92(Suppl 1):127-128.
8. Pan XQ, Shih CC, Harday J. Chitinase induces lysis of MCF-7 cells in culture and of human breast cancer xenograft B11-2 in SCID mice. Anticancer Res, 2005,25:3167-3172.
9. Sanders NN, Eijsink VG, Pangaart PS, et al. Mucolytic activity of bacterial and human chitinase. Biochim Biophys Acta, 2007,1770:839-846.
10. Pan XQ. Chitin and Chitinase in anticancer research. Musumeci S, Paoletti MG, eds. Binomium Chitin-Chitinase: Recent Issue. New York: Nova Science Publishers, 2009:183-202.
11. Hollak CE, Weely VS, Oers VMH, et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of gaucher disease. J Clin Invest, 1994,93:1288-1292.
12. Renkema GH, Boot RG, Muijsers AO, et al. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem, 1995,270:2198-2202.
13. van Eijk M, van Roomen CP, Renkema GH, et al. Characterization of human phage-derived chitotriosidase, a component of innate immunity. Int Immunol, 2005,17:1505-1512.
14. Hall AJ, Morroll S, Tighe P, et al. Human chitotriosidase is expressed in the eye and lacrimal gland and has an antimicrobial spectrum different from lysozyme. Microbes Infect, 2008,10:69-78.
15. Renkema GH, Boot RG, Au FL, et al. Chitotriosidase a chitinase, and the 39 kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem, 1998,251:504-509.
16. Tjoelker LW, Gosting L, Frey S, et al. Structural and functional definition of the human chitinase chitin-binding domain. J Biol Chem, 2000,275:514-520.
17. Renkema GH, Boot RG, Strijland A, et al. Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. Eur J Biochem, 1997,244:279-285.
18. Boot RG, Renkema GH, Strijland A, et al. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem, 1995, 270:26252-26256.
19. Sundsmo JS, Chin JR, Papin RA, et al. Factor B, the complement alternative pathway serine proteinase is a major constitutive protein synthesized and secreted by resident and elicited mouse macrophages. J Exp Med, 1985, 161:306-322.
20. Gordon S, Newman W, Bloom B. Macrophage proteases and rheumatic diseases: regulation of plasminogen activator by thymus-derived lymphocytes. Agents Actions, 1978, 8:19-26.
21. Adams DO. Effector mechanisms of cytolytically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors. J Immunol, 1980,124:286-292.
22. Somers SD, Whisnant CC, Adams DO. Quantification of the strength of cell-cell adhesion: the capture of tumor cells by activated murine macrophages proceeds through two distinct stages. J Immunol, 1986,136:1490-1496.
23. Taniguchi H, Shimada Y, Sawachi K, et al. Lipopolysaccharide-activated alveolar macrophages having cytotoxicity toward lung tumor cells through cell-to-cell binding dependent mechanism. Anticancer Res, 2010,30:3159-3166.
24. Tapping RI. Innate immune sensing and activation of cell surface toll-like receptors. Semin Immunol, 2009, 2:175-184.
25. Hino M, Kohchi C, Nishizawa T, et al. Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide. Anticancer Res, 2005,25:3747-3754.
26. Yoon TJ, Kim TJ, Lee H, et al. Anti-tumor metastatic activity of β-glucan purified from mutated Saccharamyces cerevisiae. Int Immunol, 2008,8:36-43.
27. Rhoades E, Hsu FF, Torrelles JB, et al. Identification and macrophage-activating activity of glycolipids released from intracellular mycobacterium bovis BCG. Mol Microbiol, 2003, 48:875-888.
28. Song K, Chang Y, Prud'homme GJ. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination. Gene Ther, 2000,7:481-492.
29. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumor progression. Semin Cancer Biol, 2008,18:349-355.
30. Onoe K, Yanagawa Y, Minami K, et al. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol Res, 2007,38:319-332.
31. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity and transplantation tolerance. Immunol Rev, 2001,182:18-32.
32. + regulatory T cells. J Dermatol Sci, 2009,54:69-75.
33. + T cells and macrophages: communication between two regulators of effector T cells. Inflamm Res, 2008,57:564-570.
34. + T cells in mice. Immunol Cell Biol, 2011, 89:130-142.
35. + regulatory T cells induce alternative activation of human monocytes/macrophages. PNAS USA, 2007,104:19446-19451.
36. Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol, 2010,7:164-174.
37. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011,331:1565-1570.
38. Prestwich RJ, Errington F, Hatfield P, et al. The immune system-is it relevant to cancer development, progression and treatment? Clin Oncol, 2008,20:101-112.
39. Carthay A. How do regulatory T cells work? Scand J Immunol, 2009,70:326-336.
40. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 2001,61:4766-4772.
41. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 2002,169:2756-2761.
42. Gordon S. Alternative activation of macrophages. Nat Rev Immunol, 2003,3:23-35.
43. Russell SW, Doe WF, Mcintosh AT. Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors. J Exp Med, 1977,146:1511-1520.
44. Sica A, Schioppa T, Mantovani A, et al. Tumor-associated macrophages are a distinct M2 polarised population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer, 2006, 42:717-727.
45. Hao NB, Lu MH, Fan YH, et al. Macrophages in tumor microenvironments and the progression of tumors. Clin Devel Immunol, 2012, 1-11.
46. Zaynagetdinov R, Sherrill TP, Polosukkhin VV, et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol, 2011, 187:5703-5711.
47. Schmieder A, Michel J, Schonhaar K, et al. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol, 2012, 22:289-297.
48. Shirabe K, Mano Y, Muto J, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today, 2012,42:1-7.
49. Bretscher PA, Wei G, Menon JN, et al. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmenania major. Science, 1992,257:539-542.
50. Bretscher PA, Ogunremi O, Menon JN. Distinct immunological states in murine cutaneous leishmaniasis by immunizing with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states. Behring Inst Mitt, 1997,98:153-159.
51. + T helper cell phenotype development in a T cell receptor-α β-transgenic model. J Exp Med, 1995,182:1579-1584.
52. Lentinan AT, Fenishel RL, Chirgis MA, eds. Immune Modulation Agents and Their Mechanism. New York: Marcel Dekker, 1984: 63-77.
53. Li H, Cao MY, Lee Y, et al. Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother, 2005,54:1115-1126.
54. Du C, Feng N, Jin H, et al. Preclinical efficacy of virulizin in human breast, ovarian and prostate tumor models. Anticancer Drugs, 2003,14:289-294.
55. Li H, Cao MY, Lee Y, et al. Virulizin, a novel immunotherapy agent, stimulates TNFα expression in monocytes/macrophages in vitro and in vivo. Int Immunopharmacol, 2007,7:1350-1359.
56. Benatar T, Cao MY, Lee Y, et al. Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. Cancer Immunol Immunother, 2008,57: 1757-1769.
57. Delehanty JB, Johnson BJ, Hickey TE, et al. Binding and neutrakization of lipopolysaccharides by plant proantho-cyanidins. J Nat Prod, 2007,70:1718-1724.
58. Li CQ, He LC, Jin JQ. Atractylenolide I and atractylenolide III inhibit lipopolyaccharide-induced TNF-α and no production in macrophages. Phytother Res, 2007,21:347-353.
59. Yang F, de Villiers WJ, McClain CJ, et al. Green tea polyphenols block endotoxin-induced tumor necrosis factor production and lethality in a murine model. J Nutr, 1998,128: 2334-2340.
60. + regulatory T cells suppress tumor immunity but sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 2004,34:336-344.
61. Matar P, Rozados VR, Gervasoni SI, et al. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother, 2002,50:588-596.
62. Zou JP, Yamamoto N, Fujii H, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int Immunol, 1995,7:1135-1145.
63. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immuno-therapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol, 1995,155:1393-1403.
64. Tsung K, Meko JB, Tsung YL, et al. Immune response against large tumors eradication by treatment with cyclophosphamide and IL-12. J Immunol, 1998,160:1369-1377.
65. Tsung K, Dolan JP, Tsung YL, et al. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res, 2002,62:5069-5075.
66. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 2005,105:2862-2868.
67. Le HN, Lee NC, Tsung K, et al. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide IL-12. J Immunol, 2001, 167:6765-6772.
68. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol, 1999,163:5211-5218.
69. Miettinen M, Matikainen S, Vuopio-varkila J, et al. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Inf Immunity, 1998,66:6058-6062.
70. Hessle C, Hanson LA, Wold AE. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp Immunol, 1999,116:276-282.
71. Kato I, Tanaka K, Yokokura T. Lactic acid bacterium potently induces the production of interleukin-12 and interferon-γ by mouse splenocytes. Int J Immunopharmacol, 1999,21:121-131.
72. Takeda K, Suzuki T, Shimada SI, et al. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clin Exp Immunol, 2006,146: 109-115.
73. Matsuguchi T, Takagi A, Matsuzaki T, et al. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol, 2003,10:259-266.
74. Ishikawa H, Akedo I, Otani T, et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer, 2005;116:762-767.
75. Kato I, Endo K, Yokokura T. Effects of oral administration of Lactobacillus casei on antitumor responses induced by tumor resection in mice. Int J Immunopharmacol, 1994,16:29-36.
76. Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLB study Group. Eur Urol, 1995,27:104-109.
77. Aso Y, Akazan H. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. The BLB study Group. Urol Int, 1992,49:125-129.
78. Matsuzaki T, Yokokura T, Azuma I. Antimetastatic effect of Lactobacillus casei YIT9018 (LC 9018) on a highly metastatic variant of B16 melanoma in C57BL/6J mice. Cancer Immunol Immunother, 1987,24:99-105.
79. Zhou JS, Gill HS. Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis. Int J Food Microbiol, 2005,103:97-104.
80. Seki T, Morimura S, Ohba H, et al. Immunostimulation-mediated antitumor activity by preconditioning with rice-shochu distillation residue against implanted tumor in mice. Nutr Cancer, 2008,60,776-783.
81. Seki T, Morimura S, Shigematsu T, et al. Antitumor activity of rice-shochu post-distillation slurry and vinegar produced from the post-distillation slurry via oral administration in a mouse model. Biofactors, 2004,22:103-105.
82. Vynios DH. Theocharis DA, Papgeorgakopulou N, et al. Biochemical changes of extracellular proteoglycans in squamous cell laryngeal carcinoma. Connect Tissue Res, 2008,49:239-243.
83. Iozzo RV, Cohen I. Altered proteoglycan gene expression and the tumor stroma. Experientia, 1993,49:447-455.
84. Gu Y, Mi W, Ge Y, et al. GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res, 2010,70:6344-6351.
85. Brockhausen I. Biosynthesis and functions of O-glycans and regulation of mucin antigen expression in cancer. Biochem Soc Trans, 1997,25:871-874.
86. Pan XQ, Lee R, Ratnam M. Penetration into solid tumor tissue of fluorescent latex microspheres: a mimic of liposome particles. Anticancer Res, 2004,24:3005-3008.
87. Xu L, Wang Y, Wang L, et al. Tychi, a novel chitinase with RNA N-glycosidase and anti-tumor activities. Front Biosci, 2008,13:3127-3135.
88. Henrissat B, Bairoch A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem J, 1993,293:781-788.
89. Kawase T, Yokokawa S, Saito A, et al. Comparison of enzymatic and antifungal properties between family 18 and 19 chitinases from S. coelicolor A3(2). Biosci Biotechnol Biochem, 2006,70:988-998.
90. Koprivova A, Stemmer C, Altmann F, et al. Targeted knockouts of physcomitella lacking plant-specific immunogenic N-glycans. Plant Biotechnol J, 2004,2:517-523.
91. Schahs M, Strasser R, Stadlmann J, et al. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J, 2007,5:657-663.